ArQule, Inc. to Present at Needham 12th Annual Healthcare Conference Needham Healthcare Conference 2013 Business Wire WOBURN, Mass. -- April 23, 2013 ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Needham 12^th Annual Healthcare Conference on Tuesday, April 30, 2013 at 10:40 a.m. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website, http://www.arqule.com. About ArQule ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR); ARQ 621, designed to inhibit the Eg5 kinesin motor protein; and ARQ 736, designed to inhibit the RAF kinases. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. Contact: ArQule, Inc. William B. Boni, 781-994-0300 VP, Investor Relations/ Corp. Communications www.ArQule.com
ArQule, Inc. to Present at Needham 12th Annual Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.